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Abstract
Background: Platelets play a pivotal role in the pathogenesis of acute coronary syndrome (ACS) and acute and
chronic complications following percutaneous coronary intervention (PCI). Platelet inhibition is a cornerstone in the
management of these patients. Idiopathic thrombocytopenic purpura (ITP) is a bleeding disorder characterized by
premature platelet destruction mediated by autoantibodies. The safety of antiplatelet therapy and PCI in patients
who have ACS and ITP is unknown. The aim of the present study is to discuss the management strategies for
patients who have ACS and ITP and to review limited data available in the literature.
Case presentation: We report the case of a patient with ITP who underwent three separate coronary interventions.
The first PCI with stenting was performed in the left anterior descending artery 5 years ago while the patient
suffered an anterior acute myocardial infarction, and the platelet count at admission was 90 × 109/L. The patient
presented with recurrent ACS and severe in-stent restenosis 5 years after the first PCI, and the platelet count at
admission was 18 × 109/L, and elevated to 87 × 109/L after platelets transfusion. He was treated successfully with
cutting balloon angioplasty under anticoagulation with unfractionated heparin and antiagregation with acetylsalicylic
acid and clopidogrel. Four months later after cutting balloon angioplasty, the patient received an intracoronary stent
when he once again presented with recurrent ACS in the setting of restenosis. The patient has been observed for
1.5 years without restenosis after the third PCI.
Conclusion: We reviewed all the cases in the literature involving PCI and discussed the management strategies in
patients with ITP and ACS. Available data suggest that PCI can be safe and feasible, and the risk–benefit equation of
PCI procedures and antiplatelet therapies should be carefully evaluated, and the treatment should be individualized.
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Background
Platelets play a pivotal role in the pathogenesis of acute
coronary syndrome (ACS) [1]. Treatment for ACS usually
involves antiplatelet, anticoagulant, and antithrombotic
therapy, and the performance of percutaneous coronary
intervention (PCI) [1, 2]. In addition, platelet aggregation
also plays a crucial role in the pathogenesis of acute and
chronic complications following PCI [1–3]. The combin-
ation of acetylsalicylic acid and thienopyridine derivatives
is a mainstay in the management of patients undergoing
PCI [1–3]. All of these medications are associated with
bleeding sequelae and are generally contraindicated in pa-
tients with thrombocytopenia.
Idiopathic thrombocytopenic purpura (ITP) is an auto-
immune syndrome involving antibody and cell-mediated
destruction of platelets and suppression of platelet pro-
duction that may predispose to bleeding [4]. Spontaneous
mucocutaneous bleeding is common and death from
hemorrhage occurs in approximately 5 % of the ITP pa-
tients [4]. The decision to treat ITP is based on the plate-
let count, the degree of bleeding, and the patient’s lifestyle.
Many patients with ITP require no therapy and only
careful monitoring. Treatment is indicated when platelets
are <30 × 109/L, and is generally based on steroids and
splenectomy [4]. Since the incidence of ITP is around 100
cases in 1 million persons per year, ACS patients with ITP
are seen very rare. The safety of antiplatelet therapy and
PCI in patients who have ACS and ITP is unknown, and
to our knowledge, there are no guidelines or randomized
studies to suggest treatment approaches in such patients.
We present here a case of a patient with ITP who ex-
perienced recurrent ACS and restenosis after PCI and
we discuss the management strategies, including anti-
platelet therapy.
Case presentation
A 75-year-old Chinese man was admitted to our hospital
with increasing chest pain and dyspnea upon exertion.
The chest pain developed 4 weeks previously when he
was climbing stairs, and this was relieved by several
minutes rest. He also reported that 2 day preceding
hospitalization, the pain was triggered by minimum ex-
ertion, appearing even at rest. His chest pain was charac-
terized by a squeezing pattern and this was located in
the substernal area and it radiated to his left arm. He
had no history of hypertension, hypercholesterolemia,
diabetes mellitus, smoking and drinking, and there was
no history of ischemic heart disease in his family.
Eight years ago he was diagnosed of chronic ITP, but
didn’t take any treatment. His platelet counts through
the years had always been above 60 × 109/L. This earlier
diagnosis of ITP was based on the observation of mod-
erate thrombocytopenia and antiplatelet antibodies,
with bone marrow findings consistent with the
diagnosis. Five years ago primary PCI was performed in
the proximal left anterior descending coronary artery
using a drug-eluting stent (DES) because of acute an-
terior ST-segment elevation myocardial infarction at
other hospital. At the time of the first PCI, his platelet
count had been around 90 × 109/L. He received 300 mg
of clopidogrel and 300 mg of aspirin along with 5000
units of heparin bolus before PCI. He was discharged
on aspirin 100 mg and clopidogrel 75 mg orally daily
for 1 year, and he never had bleeding before.
On physical examination, his blood pressure was 135/
70 mmHg. His heart rate was regular at 76 beats/min.
The chest was clear to auscultation and percussion bilat-
erally. There was no heart murmur. Findings of abdom-
inal and neurological examinations were unremarkable,
and lower extremities were without edema. A 12-lead
ECG recorded on admission in the patient showed nor-
mal sinus rhythm and biphasic or inverted T waves in
leads V1–3 (Fig. 1a). Blood examination revealed a plate-
let count of 18 × 109/L, mean platelet volume 13.6 fl
(normal range: 6.5–11.0), troponin I level of 0.55 ng/mL
(reference, <0.1), creatine kinase of 105 IU/L (normal
range: 38─171), total cholesterol of 4.47 mmol/l, low
density lipoprotein-cholesterol of 1.88 mmol/l, high
density lipoprotein-cholesterol of 1.40 mmol/l, trigly-
ceride of 1.29 mmol/l and fasting blood-glucose of
5.2 mmol/l. Blood coagulation tests showed a prothrom-
bin time of 12.4 s (normal range: 12–15), an international
normalized ratio of 0.97 (normal range: 0.85–1.15) and an
activated partial thromboplastin time of 35.0 s (normal:
30–45 s). Brain natriuretic peptide and chest X-ray
were normal. A transthoracic echocardiography dem-
onstrated a normal left ventricular end-diastolic in-
ternal diameter of 50 mm with a slightly decreased left
ventricular ejection fraction of 0.50. Diagnosis of ACS
(acute non-ST-segment elevation myocardial infarction)
was made. The GRACE (Global Registry of Acute
Coronary Events) risk score of the patient was 143. The
patient was administered high doses of intravenous
nitroglycerin and oral metrolol and atorvastatin. Ten
units of platelets were transfused after the patient was
assessed by a hematologist, and the platelet count ele-
vated to 87 × 109/L in the second day, and the patient
was given 300 mg of aspirin and 300 mg of clopidogrel,
prepared for a coronary artery angiography. Bolus injec-
tion of 3000 units unfractionated heparin was done at the
beginning of the coronary angiography, and the activated
clotting time (ACT) was monitored for the dose of hep-
arin required, and then additional 3000 units were added
during the PCI procedure, but GP IIb/IIIa inhibitors were
not used. Coronary angiography was carried out via the
radial artery, and revealed a 95 % in-stent restenosis in the
middle part of left anterior descending artery (LAD;
Fig. 2a, b). No other lesions were detected. The lesion in
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Fig. 1 Electrocardiography on admission and after PCI. a Electrocardiography performed on admission showing biphasic or inverted T waves in
leads V1–3. b Electrocardiography performed after PCI showing a resolution of the T wave abnormalities in V1-3
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the left anterior descending artery was treated using a cut-
ting balloon (Boston Scientific) with no complications
(Fig. 2c, d). Heparin was not administered any more after
the PCI, but combined anti-platelet therapy (aspirin 100
mg and clopidogrel 75 mg daily) was performed as usual.
The ECG showed the T wave abnormalities in V1-3 were
resolved after PCI (Fig. 1b). The patient was discharged
asymptomatically at 3 days after PCI. Neither bleeding nor
ischemic events were noted during hospitalization.
A week after discharge the platelet count was declined to
27 × 109/L, and aspirin and clopidogrel were stopped in
outpatient clinic. Oral methylprednisolone was begun
at 1 mg/kg per day and tapered over the subsequent
6 weeks. The platelet count gradually recovered to
200 × 109/L after receiving 1 week of methylprednisolone.
He continued the treatment with aspirin 100 mg/day,
and clopidogrel 75 mg/day for one month without
any further problems.
Four months later, the patient was readmitted due to
exertional chest pain he had felt for 1 month, even
though he took all the medications (aspirin, clopidogrel,
metrolol, atorvastatin and oral methylprednisolone) pre-
scribed every day. On admission, the platelet count was
124 × 109/L, ECG showed normal sinus rhythm and ST
segment depression in leads V2–5, and troponin I was
mildly elevated (0.26 ng/ml; reference, <0.1). Diagnosis
of unstable angina was made. Coronary angiography
showed a 99 % restenosis at the site of the previous
Fig. 2 Coronary angiography in a CRA projection (a) and an RAO + CAU projection (b) showing a severe in-stent restenosis of approximately 95 % in
the middle part of left anterior descending artery (arrow). Repeat left coronary angiography following successful cutting balloon angioplasty (arrow) in
a CRA projection (c) and an RAO + CAU projection (d)
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lesion and a 40 % stenosis in the proximal left circum-
flex artery (LCX; Fig. 3a, b). We used unfractionated
heparin, a dose of 100 U/kg, aspirin 300mg and clopi-
dogrel 600 mg were administrated. An activated clot-
ting time of 358 s was achieved. A 3.5∗28 mm sirolimus
eluted stent was deployed in the LAD with optimal angio-
graphic result and Thrombolysis in Myocardial Infarction
(TIMI) flow 3 in the LAD (Fig. 3c, d). There were no
bleedings during or after the procedure, and at discharge
the platelet count was 203 × 109/L.
He was then discharged on aspirin, clopidogrel, atorva-
statin and oral methylprednisolone. Clopidogrel was
discontinued 1 year after the procedure. During 18-month
follow-up, the patient remained clinically free of symp-
toms without any ischemia events or bleeding com-
plications. Coronary angiography showed stent patency
at 11 months’ follow-up (Fig. 4a, b). The platelet count
remained stable.
Results in previous case reports
Previous reports focusing on ITP patients who underwent
PCI were identified by searching PubMed and Google
Scholar. Key words used included “ITP”, “coronary artery
disease”, “ACS”, “myocardial infarction”, “angioplasty”,
Fig. 3 Coronary angiography in a CRA projection (a) and an RAO + CAU projection (b) showing a severe in-stent restenosis of approximately
99 % in the left anterior descending artery (arrow) 4 months after cutting balloon angioplasty. Repeat left coronary angiography after successful
stenting without residual stenosis (arrow) in a CRA projection (c) and an RAO + CAU projection (d)
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“PCI” and “stent”. From 1999 to January 2013, 17 studies
involving 18 patients affected by ITP who underwent PCI
were reported in the literature (Table 1) [5–21]. The mean
age of the patients was 59.7 ± 15.1 years (range 23–80
years). Eleven patients were male, and 7 patients were
female. Two patients were affected by stable angina, 4 pa-
tients by unstable angina, 6 patients by acute non-ST ele-
vation myocardial infarction, and 6 patients by acute
ST elevation myocardial infarction. Thirteen patients
(72 %) had single vessel coronary artery disease (10 pa-
tients for LAD disease, 1 patient for LCX disease, 1 patient
for right coronary artery (RCA) disease, 1 patient for
obtuse marginal branch disease), 4 patients (22 %) had
two-vessel disease, the remaining 1 patient (6 %) had
three-vessel disease. The 18 patients underwent 22 PCI
procedures. A total of 29 vessels [15 LAD (51.7 %), 8 LCX
(27.6 %), 4 RCA (13.8 %), 1 left main coronary artery (LM;
3.4 %), 1 obtuse marginal branch of LCX (3.4 %)] were
treated in the 22 PCI procedures. Re-PCI was underwent
in 4 patients (22 %), 1 patient because of acute coronary
thrombosis [6], 2 patients because of restenosis [10, 15], 1
patient because of staged procedure [17]. Transfemoral
and transradial approaches were used for PCI in 12 and
3 patients, respectively, and approach of PCI was not
specifed in remaining 3 patients. Only PTCA without
subsequent stent placement were underwent in 5 of 22
procedures (22.7 %), PCI with bare metal stent place-
ment in 13 of 22 procedures (59.1 %), and PCI with
drug-eluting stent placement in 4 of 22 procedures
(18.2 %). PCI was performed with extremely different
platelet counts, ranging from 3 × 109/L to 322 × 109/L
(mean 78.5 ± 81.5 × 109/L). Glycoprotein IIb/IIIa
inhibitors were administrated during PCI in 4 PCI pro-
cedures, clopidogrel was administrated before and dur-
ing PCI in 9 PCI procedures, ticlopidine in 1 PCI
procedure, acetylsalicylic acid in 9 PCI procedures, and
no any antiplatelet agents were administrated before
and during PCI in 5 PCI procedures. Twelve patients
(66.7 %) received steroid therapy, 10 patients (55.6 %)
received intravenous immunoglobulin (IVIG) therapy,
and platelet transfusions were completed in 4 patients
(22.2 %). One instance (5.6 %) of major bleeding (large
hematom around the puncture site of the right femoral
artery) [6] and 6 of minor bleeding (ecchymoses in 4
patients, small hematoma in 1 patient, diffuse petechiae
in 1 patient) were observed. Ten patients (55.6 %) were
discharged on double antiplatelet therapy of acetylsali-
cylic acid and clopidogrel, and 3 patients only on as-
pirin or ticlopidine, and 3 patients did not receive any
antiplatelet agent at discharge. In 2 reports, antiplatelet
therapy at discharge was not specifed.
Discussion
Platelets play an important role in the atherosclerotic
process and are intrinsically involved in the pathogenesis
of ACS [1–3]. Thrombocytosis has been correlated with
high incidence of ischemic heart disease, such as acute
myocardial infarction [22]. Since platelets play a major
role in thrombotic events, the association of ITP and
ACS is rare. Nevertheless, acute myocardial infarction
has been reported in even severely thrombocytopenic
patients [5]. This implies that some factor other than
platelet numbers alone is involved.
Fig. 4 Coronary angiography in a CRA projection (a) and an RAO + CAU projection (b) showing stent patency 11 months after stenting
performed in in-stent restenotic lesion (arrow)
Li-Sha et al. BMC Cardiovascular Disorders  (2015) 15:101 Page 6 of 11
Table 1 Case reports on percutaneous coronary intervention in patients with idiopathic thrombocytopenic purpura





before and during PCI
Treated vessels PCI and approach Treatment of ITP Bleeding Restenosis Discharge therapy
Fuchi et al.,
1999 [20] (twice)
72, F NSTEMI 59 None LAD PTCA, Femoral STER Large hematoma NA None
STEMI 23 None LAD PTCA, Femoral STERIVIGPLTT No NA
Caputo et al.,
2000 [6]
62, M Unstable angina 3 NA LAD BMS stenting,
Radial
STER No NA ASA Clop
Segal et al.,
2001 [21]
49, M NSTEMI 41 ASAClopAbciximab RCA, LCX BMS stenting,
Femoral
STER No NA ASA Clop
Kikuchi et al.,
2002 [22]
68, F STEMI 22 Ticlopidine LAD BMS stenting,
Femoral
NA No No Ticlopidine
Méndez et al.,
2004 [23]
70, M NSTEMI 170 ASAClopAbciximab RCA, LCX BMS stenting,
Radial
IVIGPLTT ECC NA NA
Stouffer et al.,
2004 [24] (twice)
77, M Unstable angina 64 ASA LCX PTCA None No yes ASA
NSTEMI 78 ASA Eptifibatide LCX BMS stenting STER Petechiae No ASA Clop
Amit et al.,
2005 [25]
46, M NSTEMI 38 ASA LAD PTCA IVIG No NA ASA
Marques et al.,
2005 [26]
54, M Unstable angina 15 None LAD, LCX BMS stenting,
Brachial
STERIVIGPLTT No NA None
Kim et al.,
2006 [27]
47, F STEMI 21 Clop RCA BMS stenting,
Femoral
IVIG ECC NA ASA Clop
Fong et al.,
2006 [28]
71, F NSTEMI 119 ASA LAD DES stenting,
Radial
STERIVIG No No ASA Clop
Park et al., 2007
[29] 3 times
61, F Stable angina 4 None None CAG, Femoral STER Hematoma No None
34 None LAD, LCX BMS stenting,
Femoral
STERIVIGPLTT No yes None
20 None LAD, LCX PTCA, Femoral STER No NA None
Gracia et al.,
2008 [30]
37, M STEMI 39 ASA Clop LAD BMS stenting,
Femoral
None No NA ASA Clop
Moretti et al.,
2008 [31] (twice)
66, M Unstable angina 110 NA RCA, LCX BMS stenting STERIVIG No NA ASA Clop
200 NA LM, LAD DES stenting,
Femoral
STER No NA ASA Clop
Can et al.,
2009 [32]
76, M Stable angina 100 Clop LAD BMS stenting,
Femoral
Danazol No NA NA
Yildiz et al.,
2010 [33]
23, F STEMI 35 Clop LAD BMS stenting,
Femoral













Table 1 Case reports on percutaneous coronary intervention in patients with idiopathic thrombocytopenic purpura (Continued)
Neskovic et al.,
2010 [34]
80, M STEMI 5 ASA Clop LAD BMS stenting,
Femoral
STER Danazol No NA ASA Clop
Torbey et al., 2013
[35] 2 cases
61, F STEMI 322 ASA Clop Abciximab LAD DES stenting,
Femoral
SPLSTERIVIG ECC NA ASA Clop




STERIVIG No yes ASA Clop
Pt patient, Y years, F femal, M male, CAD coronary artery disease, NSTEMI non-ST elevation myocardial infarction, STEMI ST elevation myocardial infarction, PCI percutaneous coronary intervention, PLT Platelet, NA data
not available, ASA acetylsalicylic acid, Clop clopidogrel, LAD left anterior descending artery, RCA right coronary artery, LCX left circumflex artery, LM left main artery, PTCA Percutaneous transluminal coronary angioplasty,













If a patient with chronic thrombocytopenia has coron-
ary artery disease, the concomitance of known coronary
risk factors, such as hypertension, diabetes, dyslipidemia,
cigarette smoking or a family history for cardiovascular
disease, should be considered. Sometimes, in patients
without these coronary risk factors like the present case,
it could be related with some other causes. First, plate-
lets in patients with ITP was larger, younger, and more
adhesive to the vascular surface [23]. In acute myocar-
dial infarction or stroke patients, mean platelet volume
is significantly increased despite a concomitant decrease
in platelet count [24–26]. In the present case, the mean
platelet volume of the patient was significantly increased.
Previous studies have demonstrated that large platelets
have a higher thrombotic potential [24–26]. Osuna et al
[27] analysed the relationship between mean platelet vol-
ume and recurrent myocardial infarction, and found that
increased mean platelet volume and platelet size contrib-
uted to reinfarction and death. Karpatkin [28] reported
that the platelet aggregation velocity was directly in pro-
portion to the platelet volume and correlated best with
the megathrombocyte index. Second, elevated platelet
microparticles in the ITP patients with ACS were ob-
served [29, 30]. Microparticles are membrane vesicles re-
leased from many different cell types, including platelets.
They have a potent pro-inflammatory effect, promote co-
agulation and affect vascular function [29, 30]. Circulating
platelet microparticles and the risk of thromboembolic
complications have repeatedly been demonstrated [29–31].
Therefore, platelet microparticles may be associated with
coronary thrombosis in patients with ITP. Third, antigenic
mimicry between platelets and endothelial cells may lead
to damage of the platelets and the endothelium, caused by
autoantibodies directed against platelet surface antigens,
notably IIb/IIIa receptors [32, 33]. Finally, a rise of the
platelet count with administration of steroids, intravenous
immunoglobulin, or platelet transfusion in ITP might be
“procoagulant” and might aggravate the potentially adverse
effect of increased plasma viscosity leading to increased
susceptibility to fatal thrombotic events, such as myocar-
dial infarction or stroke [23, 34, 35].
The combination of ITP and coronary artery disease
poses serious management problems in which a good
balance between the prevention of thrombosis and
hemorrhagic risk must be achieved. Indeed, ITP increases
risks of bleeding in general and medications to inhibit
platelet function are generally not recommended. How-
ever, antiplatelet agents should be used in patients with
coronary artery disease unless contraindication exists,
especially after stent implantation. This dilemma leads to
difficulty in managing concomitant ITP and coronary
artery disease. Performance of PCI in a patient with ITP
presents a unique situation in which platelet function
needs to be inhibited sufficiently to perform PCI safely but
not to the extent that bleeding complications result. Our
initial strategy was to treat the patient with drugs, but our
patient had refractory symptoms and ischemic ECG
changes and elevated troponin I despite therapy with
nitrates, β-blockers and statins, and revascularization was,
therefore, indicated. Since our patient was categorized as
having high risk for major bleeding and had only a single
coronary lesion, PCI was a better choice than bypass sur-
gery. We decided to administer antiplatelet agents after
platelets transfusion, and then proceed using cutting bal-
loon angioplasty without stent implantation because of
the risk of subacute stent thrombosis in a patient in whom
it was unknown whether he would be tolerant of combin-
ation therapy of acetylsalicylic acid and clopidogrel after
stent implantation. The patient was given steroids follow-
ing cutting balloon angioplasty, and the platelet count
increased and remained normal level. The patient did
receive an intracoronary stent 4 months later when he
once again presented with recurrent ACS in the setting of
restenosis. Coronary angiography showed stent patency
11 months after stent implantation.
Based on the results of the previous case reports
[5–21, 31, 36] and present report, we concluded that
PCI can be a useful strategy in patients with ITP and
severe coronary artery disease even when the patient
has severe thrombocytopenia, and major bleeding was
rare. Both transfemoral and transradial approaches
were successfully used for PCI. Implanting a bare metal
stent (BMS) appears to be reasonable choice during
PCI, since dual antiplatelet therapy with acetylsalicylic
acid and clopidogrel could be administered for a
shorter period of time to allow stent endothelialization.
DES implantation was also reported in 4 patients, and 5
cases of PCI without subsequent stent placement were
also reported. Perioperative ITP treatment certainly
minimized the complication rate in the PCI population
as well. Steroids should be first choice to increase the
platelet count, but if a rapid platelet count elevation
were required, platelet transfusions and IVIG supple-
mentation could be administered. A safe cutoff platelet
count above which invasive procedures can be performed
has not been yet established. Russo et al. [36] have sug-
gested that when the platelet counts >50 × 109/L inter-
vention either percutaneously or surgically can be
safely performed. The combined therapy of acetylsali-
cylic acid and clopidogrel after PCI was well tolerated
in most of patients. In addtion, most of patients had
single vessel coronary artery disease and LAD artery
was the most commonly occluded of the coronary ar-
teries in patient with ITP, which was the same with the
general population. Among 7 cases who underwent
reexamined coronary angiography, 3 patients had cor-
onary restenosis. The restenosis developed after per-
cutaneous transluminal coronary angioplasty without
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stent placement in 1 patient, after BMS implant in 1
patient, and after DES implant in 1 patient. The pre-
sent case also occurred repeatedly in-stent restenosis.
Repeat revascularization was successfully done in all 4
patients. Many factors may be involved in the patho-
physiology of restenosis. Norgaz et al [37] found that
mean platele volume before PCI is correlated with
subsequent development of in-stent restenosis, and if
preprocedural mean platele volume is greater than
8.4 fl, restenosis is more probable to occur. Generally,
The mean platelet volume in patients with ITP was sig-
nificantly increased. Therefore, platelet size may play a
role in the development of restenosis after PCI in a patient
with ITP.
Conclusions
Available data suggest that PCI can be safe and feasible,
and the risk–benefit equation of PCI procedures and
antiplatelet therapies should be carefully evaluated, and
the treatment should be individualized.
Consent statement
Written informed consent was obtained from the
patient for publication of this case report and any
accompanying images.
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